New Inhaled Antimicrobial Formulations for Use in the Cystic Fibrosis Patient Population.

Link to article at PubMed

New Inhaled Antimicrobial Formulations for Use in the Cystic Fibrosis Patient Population.

Ann Pharmacother. 2015 Dec 20;

Authors: Campbell CT, McCaleb R, Manasco KB

OBJECTIVE: To review the current literature on inhaled antibiotic therapies currently in clinical trials for cystic fibrosis (CF) patients.
DATA SOURCES: A literature search was performed using PubMed (1975 to September 2015), International Pharmaceutical Abstracts (1970 to September 2015), and MEDLINE (1946 to September 2015) to identify studies for inclusion. The following search terms were used: cystic fibrosis, inhaled amikacin, inhaled liposomal amikacin, inhaled vancomycin, and/or inhaled levofloxacin.
STUDY SELECTION AND DATA EXTRACTION: All English-language phase II to III studies evaluating efficacy and/or safety, case reports, and retrospective studies of inhaled amikacin, inhaled vancomycin, and inhaled levofloxacin in CF patients were included.
DATA SYNTHESIS: Currently available inhaled antibiotics, tobramycin and aztreonam, have demonstrated improvement in respiratory function of CF patients. Newer agents have shown potentially similar efficacy, with improvement in ease of use. Limited data suggest that inhaled liposomal amikacin and levofloxacin are both noninferior to tobramycin in terms of improvements in respiratory function. Inhaled levofloxacin has a lower rate of hospitalizations secondary to respiratory exacerbations and a reduction in the Pseudomonas aeruginosa sputum density compared with inhaled tobramycin. Inhaled vancomycin use has been documented in case reports and 2 small retrospective eradication trials, although data are limited to support its use.
CONCLUSIONS: The horizon of inhaled antibiotic choices for CF patients is promising. The introduction of different drug classes and formulations to treat resistant Gram-negative and Gram-positive organisms increases the number of options for patients for both eradication and treatment of chronic colonization.

PMID: 26692274 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *